The present invention relates to a pharmaceutical combination, such as a combined preparation or pharmaceutical composition, respectively, comprising at least one DGAT1 inhibitor, or a pharmaceutically acceptable salt or ester thereof, at least one kind of triglyceride lowering drug selected from the group consisting of (a) at least one PPAR alpha agonist or a pharmaceutically acceptable salt thereof or ester thereof, and (b) at least one compound selected from the group consisting of (i) natural or synthetic omega-3 fatty acids or pharmaceutical acceptable esters, derivatives, conjugates, precursors or salts thereof or mixtures thereof, or (ii) omega-3 oils, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of hypertriglyceridemia, in particular chylomicronemia (also called hyperchylomicronemia) a pharmaceutical composition comprising such a combination the use of such a combination for the preparation of a medicament for the treatment of hypertriglyceridemia, in particular chylomicronemia (also called hyperchylomicronemia a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use and to a method of treatment of a warm-blooded animal, especially a human.La présente invention concerne une combinaison pharmaceutique, telle quune préparation ou une composition pharmaceutique combinée, respectivement, comprenant au moins un inhibiteur de DGAT1, ou un sel ou un ester pharmaceutiquement acceptable de celui-ci, au moins une sorte de médicament abaissant la teneur en triglycérides choisi dans le groupe consistant en (a) au moins un agoniste de PPAR alpha ou un sel pharmaceutiquement acceptable de celui-ci ou un ester de celui-ci, et (b) au moins un composé choisi dans le groupe consistant en (i) les acides gras oméga-3 naturels ou synthétiques ou les esters, dérivés, conjugués, précurseurs ou sels pharmaceutiq
